siRNA targeting the VP1 protein of FMDV effectively inhibits viral replication in vitro and in vivo, highlighting its potential as an antiviral therapy.
Answers are grounded in this paper and cite their sources.
siRNA targeting VP1 shows in vivo antiviral activity in mice; leaves open translation to livestock or therapeutic use.
RNA interference (RNAi) is a powerful tool to silence gene expression posttranscriptionally. In this study, we evaluated the antiviral potential of small interfering RNA (siRNA) targeting VP1 of foot-and-mouth disease virus (FMDV), which is essential during the life cycle of the virus and plays a key role in virus attachment to susceptible cells. We investigated in vivo the inhibitory effect of VP1-specific siRNAs on FMDV replication in BHK-21 cells and suckling mice, a commonly used small animal model. The results showed that transfection of siRNA-expressing plasmids gave an 80 to 90% reduction in the expression of FMDV VP1 in BHK-21 cells. Moreover, BHK-21 cells transiently transfected with siRNA-expressing plasmids were specifically resistant to FMDV infection when exposed to 100 50% tissue culture infective doses of virus, and the antiviral effects extended to almost 48 h postinfection. Furthermore, subcutaneous injection of siRNA-expressing plasmids in the neck made suckling mice significantly less susceptible to FMDV. In conclusion, our data suggests that RNAi may provide a viable therapeutic approach to treat FMDV infection.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: